Key clinical point: Chemotherapy-free front-line treatment with dalpiciclib plus pyrotinib demonstrated promising efficacy and manageable safety in patients with human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer (BC).
Major finding: At a median follow-up of 25.9 months, 28 (70%) patients had a confirmed objective response, with 2 and 26 patients achieving complete and partial responses, respectively. Grades 3 and 4 treatment-related adverse events were reported by 82.9% and 12.2% of patients respectively, and of these, decreased white blood cells, decreased neutrophil count, diarrhea, and anemia were the most common.
Study details: Findings are from a single arm phase 2 study including 41 patients with HER2+ advanced BC who received front-line treatment with dalpiciclib+pyrotinib.
Disclosures: This study was funded by the XINRUI Project of Cancer Supportive Care and Treatment Research, China. H Li declared serving as an employee of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Shanghai, China) during the study period.
Source: Yan M et al. Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: A single-arm phase II trial. Nat Commun. 2023;14:6272 (Oct 7). doi: 10.1038/s41467-023-41955-7